# US 2022/0018856 A1 · Antibody conjugate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0018856 A1
- Document ID: US20220018856A1
- Status: Published application
- Kind: A1
- Application number: 17/294,931
- Filed: 2019-11-21
- Published: 2022-01-20
- Earliest claimed: 2018-11-22
- Assignees: Fujirebio Inc.
- Applicants: Fujirebio Inc.
- Inventors: Geert JANNES; Martine DAUWE; Yuichi ISHII; Ryo OKADA
- Web page: https://patentgrep.com/patent/US20220018856A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- C07K 16/18: against material from animals or humans
- C07K 17/14: Peptides being immobilised on, or in, an inorganic carrier
- G01N 33/535: with enzyme label {or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates}
- G01N 33/54326: {Magnetic particles}
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/35: Valency
- G01N 2333/4709: Amyloid plaque core protein
- G01N 2440/14: phosphorylation
- G01N 2800/2821: Alzheimer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides an improvement of sensitivity in immunological measurement of tau protein. Specifically, the present invention provides an antibody conjugate comprising two or more kinds of anti-tau protein antibodies bound to a carrier.

## Claims

### Claim 1

An antibody conjugate comprising two or more kinds of anti-tau protein antibodies bound to a carrier.

### Claim 2 (depends on 1)

The antibody conjugate according to claim 1, wherein the two or more kinds of anti-tau protein antibodies are two or more kinds of anti-human tau protein antibodies.

### Claim 3 (depends on 2)

The antibody conjugate according to claim 2, wherein the two or more kinds of anti-tau protein antibodies comprise a first antibody that recognizes an epitope present between positions 153 and 169 in the amino acid sequence of SEQ ID NO:1 and a second antibody that recognizes an epitope present between positions 188 and 207 in the amino acid sequence of SEQ ID NO:1.

### Claim 4 (depends on 3)

The antibody conjugate according to claim 3, wherein the epitope recognized by the first antibody is PPGQK (SEQ ID NO:2) and the epitope recognized by the second antibody is DRSGYS (SEQ ID NO:3).

### Claim 5 (depends on 1)

The antibody conjugate according to claim 1, wherein the carrier is a labeled carrier.

### Claim 6

A kit comprising:
(i) an antibody conjugate comprising two or more kinds of anti-tau protein antibodies bound to a carrier; and
(ii) an anti-tau protein antibody that recognizes an epitope different from epitopes recognized by the anti-tau protein antibodies comprised in the antibody conjugate.

### Claim 7 (depends on 6)

The kit according to claim 6, wherein said different epitope is an epitope present between positions 170 and 187 or an epitope present between positions 209 and 233 in the amino acid sequence of SEQ ID NO:1.

### Claim 8 (depends on 7)

The kit according to claim 7, wherein said different epitope is PPAPKTP (SEQ ID NO:4) or PPTREPK (SEQ ID NO:5).

### Claim 9

A method for detecting tau protein, comprising detecting the tau protein in a sample using an antibody conjugate comprising two or more kinds of anti-tau protein antibodies bound to a carrier.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the sample is a body fluid sample collected from a human being.

### Claim 11 (depends on 9)

The method according to claim 9, further comprising contacting the sample with an anti-tau protein antibody that recognizes an epitope different from epitopes recognized by the anti-tau protein antibodies comprised in the antibody conjugate.
